Arcellx Inc (ACLX NASDAQ) stock market data APIs
$74.5173
0.83(1.1%)
as of December 8, 2025
Try our APIs with
free plan!
Arcellx Inc Financial Data Overview
Price chart is built with
Anychart
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Prev. Close
74.5173
Open
75.3428
High
80.544
Low
69.3059
52 wk Range
47.8601-94.07
Market Cap
4 022 M
Shares Outstanding
57 823 K
Revenue
35 898 K
EPS
-0.99
Beta
0.338
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Arcellx Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Arcellx Inc data using free add-ons & libraries
Get Arcellx Inc Fundamental Data
Arcellx Inc Fundamental data includes:
- Net Revenue: 35 898 K
- EBITDA: -235 726 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-17
- EPS/Forecast: -0.9605
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Arcellx Inc News
New
Assessing Arcellx (ACLX) Valuation Following Positive Pivotal CAR T Data and Commercial Launch Plans
Arcellx (ACLX) just put fresh Phase 2 iMMagine-1 data for its multiple myeloma CAR T, anitocabtagene autoleucel, on the table, and the results look clinically meaningful for both patients and sharehol...
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
– 96% Overall Response Rate, 74% Stringent Complete Response/Complete Response, and 95% Minimal Residual Disease Negativity Observed at a Median 15.9-months of Follow-up, with Responses Continuing t...
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
-- Anito-cel demonstrated 96% ORR and 74% CR/sCR at a median follow-up of 15.9 months; responses continue to deepen over time -- -- Overall MRD negativity was 95% and sustained MRD negativity for >6 ...
CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting
Arcellx, Inc. (NASDAQ:ACLX) is included in our list of the 12 oversold global stocks to invest in.CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting On November 25, ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
